MMRF PRESS RELEASES
The Multiple Myeloma Research Foundation (MMRF) Issues Statement Regarding Oncologic Drugs Advisory Committee (ODAC) Recommendation for Carfilzomib for Multiple Myeloma
Norwalk, CT — June 20, 2012
The Multiple Myeloma Research Foundation (MMRF) today issued the following statement regarding the Oncologic Drugs Advisory Committee (ODAC) panel’s vote recommending approval of Kyprolis™ (proposed trade name for carfilzomib, Onyx Pharmaceuticals) for the treatment of patients with relapsed and refractory multiple myeloma. “This is an extremely important endorsement of Kyprolis (carfilzomib) for multiple myeloma patients, as it marks the potential for a new and much-needed treatment option to become widely available for patients with multiple myeloma who are no longer responding to available therapies.
“Despite the approval of four new treatments between 2003 and 2007, nearly all patients eventually relapse or become refractory to treatment. The five-year relative survival rate for multiple myeloma is approximately 38%, one of the lowest of all cancers, making it critical that we have new treatments like Kyprolis that specifically target these patient populations.
“We are pleased that ODAC recognized the clinically meaningful benefit that carfilzomib has brought to patients throughout its clinical program,” said Walter Capone, Chief Operating Officer of the MMRF. “We look forward to learning the results of the FDA review, and will continue to support our partner Onyx as they work with the FDA in the coming weeks to hopefully bring this therapy to patients.”
About the Multiple Myeloma Research Foundation (MMRF) and Onyx Pharmaceuticals Partnership for Kyprolis™
The MMRF facilitated early Phase 1 clinical work and three Phase 2 trials with carfilzomib within the MMRF network, including the pivotal Phase 2b trial that supported the ODAC positive recommendation for the therapy. The MMRF provided access to its network of clinical experts, secured trial investigators, supplied centralized contracts, provided guidance on site selection and protocol design, and accrued patients to ensure that carfilzomib clinical work was done in the most high-quality and efficient way possible to benefit patients.
About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $200 million since its inception and directs 90% of total budget to research and related programming. As a result, the MMRF has been awarded Charity Navigator’s coveted four star rating for nine consecutive years, the highest designation for outstanding fiscal responsibility and exceptional efficiency. For more information about the MMRF, please visit www.themmrf.org.
Anne Quinn Young, MMRF
203-536-8691 | QuinnYoungA@themmrf.org